A new AIDS vaccine developed by the China Center of Disease Control and Beijing Bioproducts Institute passes phase I clinical test (Ia) and the vaccine proves to be safe and effective.

The DNA and recombinant VTT vaccine candidates (rVTT) expressing HIV-1 CRF 07 gag, pol env and nef genes have been developed.  The first approach is to use a novel vector, replicating vaccinia virus TianTan (VTT) vector, different from the usual design for AIDS vaccine.   The vaccine is now entering phase II clinical test (Ib).  More study will ensue if the test comes positive.

(China IP News)